89C8-ACE2

A biparatopic antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

89C8-ACE2 is a fusion antibody with epitopes for both the SARS-CoV-2 spike protein N-terminal domain and the ectodomain of ACE2 (Miao et al., 2020).

Link	Tested on	Impact factor	Notes	Publication date
A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy Spike protein ACE2 In vitro Antibody	Vero E6 cells; CHO cells or HEK293T cells expressing ACE2	4.63	Potent SARS-CoV-2 spike protein binding and neutralizing activity in vitro.	Aug/17/2020